Breast Cancer

One breast cancer and melanoma survivor thinks about the long-term impacts of her cancer diagnosis and the silver linings.

Cancer survivors need to keep up with the news. However, reading about a new study or risk factor might make us worry about past choices and/or current options, in a way we can't quite control.

Reflecting on the lessons learned from the trauma of living with a stage four cancer diagnosis.

We remember big events like births, deaths, marriages and holidays, but sometimes it's the little acts of kindness we remember the most.

Each new year, many make resolutions for change. For the person with cancer, resolutions are important but also need to be realistic.

One survivor reflects on life after cancer on "cannoli Monday."

One male breast cancer survivor reflects on revolutionary developments from the San Antonio Breast Cancer Symposium.

Sometimes the imperfections in life can bring an unexpected beauty. A famous mystery author explores this idea.

An improved app sends clinical trials straight to the phone of this patient with breast cancer (and she can forward them right to her doctor).

Young women and women of color with breast cancer, as well as those with metastatic disease, had the chance to experience SABCS 2019 and advocate for representation of their patient groups in ongoing clinical trials.

A diagnosis of breast cancer can cause a person to become very fearful especially when the future holds so many unknowns, but it’s not healthy to live under an umbrella of fear. In this article, survivor, Bonnie Annis, shares her experience.

A male breast cancer survivor examines the invisibility factor in this disease.

Patients with unresectable or metastatic HER2-positive breast cancer now have a new treatment option.

They're billed as "nothing", but for this patient with cancer, the tattoos are daily reminders of her new life.

Some beauty products could contain harmful ingredients. For the person with cancer, it’s important to know which options are the safest.

At the 2019 San Antonio Breast Cancer Symposium, Khevin Barnes advocated on behalf of men with breast cancer, but also advocated for more men with breast cancer to join him.

Patients with early-stage triple-negative breast cancer who did not have circulating tumor DNA in their blood experienced superior outcomes to chemotherapy followed by surgery.

Whether we have cancer or not, gratitude enriches our lives and there are many things to be grateful for.

Residual cancer burden can help physicians pinpoint accurate long-term predictions about the likelihood that a patient’s breast cancer will return.

Women who took estrogen alone as hormone therapy for their menopause experienced decreased rates of breast cancer and death from the disease even after they stopped taking the therapy, when compared to women who took estrogen with progestin.

Survival and recurrence rates were similar among patients with breast cancer who either received accelerated partial breast irradiation or whole breast irradiation.

This massive event for women with breast cancer just may be “man’s breast friend”.

Women treated with Arimidex for five years were 50% less likely to have developed breast cancer recurrence compared with women given placebo at nearly 11 years follow-up after stopping treatment.

Adding Tecentriq to chemotherapy before surgery did not improve the rate of pathologic complete response in patients with advanced, early-stage triple-negative breast cancer.

Nearly 65% of patients whose disease had spread to lymph nodes showed no signs of cancer following a regimen of Keytruda plus chemotherapy compared with those who received chemotherapy alone.

Results from a phase 3 trial showed significant increases in five-year invasive disease-free survival estimates among Japanese patients with hormone receptor-positive, HER2-negative breast cancer.

Researchers found that the addition of Perjeta to Herceptin plus chemotherapy reduced the relative risk for breast cancer recurrence or death in patients with operable HER2-positive early breast cancer, according to a six-year follow-up.

The HER2-targeted antibody-drug conjugate T-DXd achieved a response in 60.9% of patients, according to phase 2 study findings.

The label of being a cancer survivor can be simple, but underneath it can mean something so different to each person. Only you can choose what the idea of survivorship means to your journey.